SEC Tracker
Get the app
OTLC · XBRL financial data

Oncotelic Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (OTLC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue700*—————————250
Research and development2111*000—00—year only10
General and administrative34102*167968033*101664912,525*1,8531,093
Total operating expenses56113*167973,28131*101664912,529*1,8531,094
Operating income (loss)14(113)*(167)(97)(3,281)(31)*(101)(66)(491)(2,529)*(1,853)(844)
Interest expense185208*235————208———318
Income tax expense (benefit)—————————year only——
Net income (loss)115(736)*(409)(210)(3,304)(601)*(299)278(1,047)250,348*(2,194)388
Earnings per share, basic USD per share0.000.00*0.000.00(0.01)0.00*0.000.000.000.57*0.000.00
Earnings per share, diluted USD per share0.00—0.000.00(0.01)—0.000.00——0.000.00
Weighted average shares, basic thousands of shares397,777400,049*399,379401,596407,290409,236*407,423408,293426,435441,596*443,801447,387
Weighted average shares, diluted thousands of shares397,777—399,379401,596407,290409,236*407,423452,809——443,801467,914

Balance sheet

CSV

Fiscal quarters (OTLC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents268170189721498679884098964186
Accounts receivable191919191919191945122
Prepaid and other current assets—————9———1,0381,9791,253
Total current assets3662722311922391341251381,6131,1982,0651,461
Goodwill5,9885,9885,9885,9882,7882,7882,7882,7882,7882,7882,7882,788
Total assets30,09630,01529,97429,93526,78226,67726,66826,68128,156393,088393,955394,751
Total current liabilities17,11116,50516,51216,20416,35719,20019,48519,28720,08018,14318,40417,907
Total liabilities—18,40318,72518,43218,65019,20019,48519,28720,080131,357131,743131,311
Retained earnings (accumulated deficit)(32,781)(33,517)(33,925)(34,135)(37,440)(38,041)(38,339)(38,062)(39,109)211,239209,045209,434
Total stockholders' equity12,54912,13011,83412,1578,8538,2528,0238,3019,051262,761263,286264,561
Total liabilities and equity30,09630,01529,97429,93526,78226,67726,66826,68128,156393,088393,955394,751
Common shares outstanding (cover page) thousands of shares399,184399,684399,684406,270407,290408,292408,292434,930440,778444,197444,497457,513

Cash flows

CSV

Fiscal quarters (OTLC's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)115(736)*(409)(210)(3,304)(601)*(299)278(1,047)250,348*(2,194)388
Stock-based compensation—————————2,195*1,642730*
Net cash from operating activities(249)*(373)*(231)(262)*(143)*(104)*(167)(126)*(307)*year only(342)(92)*
Proceeds from issuing common stock———————————7
Net cash from financing activities335*275*250145*220*41*160135*628*463*317215*
Net change in cash86*(98)*19(117)*77*(63)*(7)9*321*(320)*(25)122*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Oncotelic Therapeutics186250(92)*457.5M2.0 quarters 10-QJun 30, 2026
TherapeuticsMD9,189not reportednot reported11.6M— 10-QJun 30, 2026
Artelo Biosciences4,198not reported(5,033)*4.6M0.8 quarters 10-QJun 30, 2026
Bioxytran177not reported(350)*114.7M0.5 quarters 10-QJun 30, 2026
Raphael Pharmaceutical1not reported0*20.2M— 10-QJun 30, 2026
Alaunos Therapeutics1240(300)*2.5M0.4 quarters 10-QJun 30, 2026
GT Biopharma4,960not reported(4,260)*45.1M1.2 quarters 10-QJun 30, 2026
BioCardia4,117not reported(1,735)*15.1M2.4 quarters 10-QJun 30, 2026
Traws Pharma5,016not reported(7,504)*15.4M0.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.